La inhibición de KRAS con CD47 y el punto de control inmune supera la resistencia intrínseca a la terapia combinada de KRAS y el punto de control inmune
Contact us if these videos are not relevant.
Contact us if these videos are not relevant.
Ver abstracta en PubMed
Resumen
Este resumen es generado por máquina.Los inhibidores de KRAS G12C para el cáncer de pulmón pueden ser mejorados. El bloqueo de CD47 y PD-L1 con inhibidores de KRAS mejora la inmunidad antitumoral y la supervivencia en modelos preclínicos.
Área De La Ciencia
- En el campo de la oncología
- Inmunología
- Biología molecular
Sus Antecedentes
- Los inhibidores de KRAS G12C ofrecen nuevas vías de tratamiento para el cáncer de pulmón, pero tienen una eficacia limitada.
- Las células tumorales pueden evadir las respuestas inmunológicas, lo que dificulta la eficacia del tratamiento.
Objetivo Del Estudio
- Investigar los mecanismos por los cuales la inhibición de KRAS afecta la inmunidad antitumoral.
- Para explorar las terapias combinadas que involucran la inhibición de KRAS, el bloqueo de CD47 y los inhibidores del punto de control inmune.
Principales Métodos
- Análisis de la expresión de CD47 y CD24 después de la inhibición de KRAS en modelos de cáncer de pulmón.
- Investigó las funciones de FOXA1 y GRHL2 en la regulación de CD47 y CD24.
- Se evaluó la eficacia de la combinación de inhibidores de KRAS con anticuerpos anti-CD47 y anti-PD-L1 en modelos murinos.
Principales Resultados
- La inhibición de KRAS G12C aumenta la regulación de CD47 y CD24, promoviendo el escape inmune de la fagocitosis de los macrófagos.
- El anticuerpo anti-CD47 restaura la fagocitosis, pero induce la expresión de PD-L1, suprimiendo la activación de las células T CD8.
- La terapia combinada (inhibidor de KRAS, anti-CD47, anti-PD-L1) logró una supervivencia a largo plazo en modelos resistentes.
Conclusiones
- Dirigirse a KRAS, CD47 y PD-L1 simultáneamente es una estrategia prometedora para el cáncer de pulmón mutante KRAS G12C.
- Esta terapia combinada puede ser particularmente eficaz en los tumores inmunológicos, superando la resistencia a la inhibición de KRAS y la inmunoterapia.
Contact us Si estos videos no son relevantes.
Contact us Si estos videos no son relevantes.
Videos de Conceptos Relacionados
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...